Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Global Markets Direct | PRODUCT CODE: 1109655

Cover Image

PUBLISHER: Global Markets Direct | PRODUCT CODE: 1109655

Bacterial Conjunctivitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

PUBLISHED:
PAGES: 31 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 2000
PDF (Site License)
USD 4000
PDF (Global License)
USD 6000

Add to Cart

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bacterial Conjunctivitis - Drugs In Development, 2022, provides an overview of the Bacterial Conjunctivitis (Ophthalmology) pipeline landscape.

Bacterial conjunctivitis is an inflammation of the conjunctiva caused by pathogenic bacteria. Bacterial conjunctivitis is usually caused by Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus sp, or, less commonly, Chlamydia trachomatis. Symptoms include redness in the white of the eye or inner eyelid, itchy eyes, blurred vision, increased sensitivity to light and burning eyes. Treatment includes antibiotics.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bacterial Conjunctivitis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Bacterial Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bacterial Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Bacterial Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 2, 1, 2 and 1 respectively.

Bacterial Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bacterial Conjunctivitis (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Bacterial Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bacterial Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bacterial Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bacterial Conjunctivitis (Ophthalmology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bacterial Conjunctivitis (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bacterial Conjunctivitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Product Code: GMDHC22229IDB

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Bacterial Conjunctivitis - Overview
  • Bacterial Conjunctivitis - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Bacterial Conjunctivitis - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Bacterial Conjunctivitis - Companies Involved in Therapeutics Development
  • Cellics Therapeutics Inc
  • IACTA Pharmaceuticals Inc
  • NTC srl
  • TaeJoon Pharmaceuticals Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • TGV-Inhalonix Inc
  • Bacterial Conjunctivitis - Drug Profiles
  • CTI-005 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • CTO-0101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • IC-702 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • ketorolac tromethamine + levofloxacin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Mul-1867 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • SHP-640 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • Bacterial Conjunctivitis - Dormant Projects
  • Bacterial Conjunctivitis - Product Development Milestones
  • Featured News & Press Releases
  • Jan 17, 2022: Lupin skids as failed USFDA specifications lead to recalls of 2 drugs
  • Nov 07, 2021: Lupin recalls Gatifloxacin in US market
  • Oct 03, 2013: Lupin launches Generic ZYMAXID Ophthalmic solution in the US
  • Aug 28, 2013: Lupin Receives FDA Approval For Gatifloxacin Eye Drops
  • Jul 01, 2013: Lupin Gets FDA Tentative Approval For Gatifloxacin Eye Drops
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Product Code: GMDHC22229IDB

List of Tables

List of Tables

  • Number of Products under Development for Bacterial Conjunctivitis, 2022
  • Number of Products under Development by Companies, 2022
  • Products under Development by Companies, 2022
  • Number of Products by Stage and Target, 2022
  • Number of Products by Stage and Mechanism of Action, 2022
  • Number of Products by Stage and Route of Administration, 2022
  • Number of Products by Stage and Molecule Type, 2022
  • Bacterial Conjunctivitis - Pipeline by Cellics Therapeutics Inc, 2022
  • Bacterial Conjunctivitis - Pipeline by IACTA Pharmaceuticals Inc, 2022
  • Bacterial Conjunctivitis - Pipeline by NTC srl, 2022
  • Bacterial Conjunctivitis - Pipeline by TaeJoon Pharmaceuticals Co Ltd, 2022
  • Bacterial Conjunctivitis - Pipeline by Takeda Pharmaceutical Co Ltd, 2022
  • Bacterial Conjunctivitis - Pipeline by TGV-Inhalonix Inc, 2022
  • Bacterial Conjunctivitis - Dormant Projects, 2022
  • Bacterial Conjunctivitis - Dormant Projects, 2022 (Contd..1)

List of Figures

List of Figures

  • Number of Products under Development for Bacterial Conjunctivitis, 2022
  • Number of Products under Development by Companies, 2022
  • Number of Products by Targets, 2022
  • Number of Products by Stage and Targets, 2022
  • Number of Products by Mechanism of Actions, 2022
  • Number of Products by Stage and Mechanism of Actions, 2022
  • Number of Products by Routes of Administration, 2022
  • Number of Products by Stage and Routes of Administration, 2022
  • Number of Products by Molecule Types, 2022
  • Number of Products by Stage and Molecule Types, 2022
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!